Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Статья

Stealth Polydopamine-Based Nanoparticles with Red Blood Cell Membrane for the Chemo-Photothermal Therapy of Cancer

Haijun WangCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, ChinaGareth R. WilliamsUCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, U.KXiaotian XieCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, ChinaMeng–Huang WuCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, ChinaJunzi WuCollege of Basic Medicine, Yunnan University of Chinese Medicine, Kunming 650500, ChinaZhu Li-minCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, China
2020en
ABI

Аннотация

Herein, we developed curcumin (Cur)-loaded porous poly(lactic-co-glycolic acid) (pPLGA) nanoparticles (NPs) by the nanoprecipitation method. Dopamine (DA) was then self-polymerized to form a polydopamine (PDA) layer on the surface of the NPs, yielding Cur@pPLGA/PDA NPs that are able to act as both chemotherapeutic and photothermal agents. These NPs were further camouflaged with the red blood cell membrane (RBCM) to construct RBCM-Cur@pPLGA/PDA NPs. The RBCM-pPLGA/PDA NPs were around 200 nm in size and demonstrated photothermal performance in the near-infrared (NIR) region, with a potent conversion efficiency (35.2%). The blank carrier has favorable cytocompatibility, but when drug loaded the NPs can efficiently induce the death of cancer cells (particularly when combined with NIR laser treatment). Cellular uptake results revealed greater in vitro uptake of RBCM-Cur@pPLGA/PDA NPs than bare Cur@pPLGA/PDA NPs in the case of cancer cells but reduced macrophage phagocytosis. In vivo studies in mice showed that the RBCM-Cur@pPLGA/PDA NPs exhibited prolonged blood circulation times and excellent photothermal properties, allowing tumor-specific chemo-photothermal therapy. The RBCM-Cur@pPLGA/PDA NP platform presents great potential for targeted synergistic cancer treatments.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 2Использованных источников: 0